Table 2

Clinical management and outcomes of patients with BRUE

n (%)
Clinical management
Hospital admission665 (63.8)
 Length of stay, days [IQR]1.73 [1.00, 3.00]
ICU admission67 (10.1)
 Length of stay, days [IQR]3.00 [1.50, 6.50]
Treatments
 Antiepileptics17 (1.6)
 Antimicrobials80 (7.7)
 Acid suppression or antireflux medications160 (15.4)
 Nasogastric feeds16 (1.5)
 Intravenous fluids59 (5.7)
 Caffeine24 (2.3)
 Oxygen (low-flow nasal prongs, or high flow)29 (2.8)
 Positive pressure ventilation (CPAP or BiPAP)12 (1.2)
CPR training offered140 (13.4)
Complications162 (15.5)
 False positive testing127 (12.2)
 Non-clinically significant events on monitors43 (4.1)
 Intravenous extravasation2 (0.2)
 Significant surgical complications1 (0.1)
 Other11 (1.1)
Diagnostic testing*855 (82.1)
Consultations440 (42.2)
Clinical outcomes
Underlying diagnosis‡
 Serious79 (7.6)
 Non-serious412 (39.5)
 N/A (unexplained)551 (52.9)
Recurrent event163 (15.6)
 During index visit113 (10.8)
 After discharge‡65 (6.2)
Return visit‡216 (20.7)
 Return visit‡—related to BRUE92 (8.8)
 Rehospitalisation‡64 (6.1)
Death‡1 (0.1)
  • *Diagnostic testing included laboratory testing (bloodwork, urine or cerebral spinal fluid studies, imaging and ancillary testing).

  • †Consultations included evaluation by specialists or allied healthcare providers.

  • ‡At or within 90 days of index presentation.

  • BiPAP, bilevel positive airway pressure; BRUE, brief resolved unexplained event; CPAP, continuous positive airway pressure; CPR, cardiopulmonary resuscitation; ICU, intensive care unit.